JP Morgan Chase
RNAC icon

JP Morgan Chase’s Cartesian Therapeutics RNAC Stock Holding History

JP Morgan Chase’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.9K Sell
4,413
-1,476
-25% -$10.5K ﹤0.01% 6455
2025
Q4 		$42.5K Sell
5,889
-235
-4% -$1.9K ﹤0.01% 6292
2025
Q3 		$62.6K Buy
6,124
+44
+0.7% +$495 ﹤0.01% 6144
2025
Q2 		$63.2K Sell
6,080
-188,957
-97% -$2.01M ﹤0.01% 5813
2025
Q1 		$2.57M Sell
195,037
-79,703
-29% -$1.42M ﹤0.01% 3684
2024
Q4 		$4.92M Sell
274,740
-34,278
-11% -$694K ﹤0.01% 3359
2024
Q3 		$4.98M Buy
309,018
+2,688
+0.9% +$42K ﹤0.01% 3219
2024
Q2 		$8.27M Buy
306,330
+258,825
+545% +$6.18M ﹤0.01% 2622
2024
Q1 		$926K Sell
47,505
-1,855
-4% -$39.3K ﹤0.01% 4404
2023
Q4 		$1.02M Sell
49,360
-674
-1% -$20.1K ﹤0.01% 4317
2023
Q3 		$1.59M Sell
50,034
-18,194
-27% -$608K ﹤0.01% 3727
2023
Q2 		$2.29M Buy
68,228
+1,692
+3% +$60.6K ﹤0.01% 3441
2023
Q1 		$2.77M Sell
66,536
-845
-1% -$39.7K ﹤0.01% 3293
2022
Q4 		$2.29M Sell
67,381
-200
-0.3% -$8.51K ﹤0.01% 3462
2022
Q3 		$3.32M Buy
67,581
+11,761
+21% +$646K ﹤0.01% 3076
2022
Q2 		$2.19M Buy
55,820
+14,777
+36% +$438K ﹤0.01% 3464
2022
Q1 		$1.51M Sell
41,043
-2,881
-7% -$180K ﹤0.01% 3971
2021
Q4 		$4.3M Sell
43,924
-17,859
-29% -$1.92M ﹤0.01% 3194
2021
Q3 		$7.71M Buy
61,783
+210
+0.3% +$25.4K ﹤0.01% 2638
2021
Q2 		$7.72M Buy
61,573
+9,684
+19% +$1.15M ﹤0.01% 2665
2021
Q1 		$7.04M Buy
51,889
+18,761
+57% +$2.33M ﹤0.01% 2677
2020
Q4 		$3.01M Buy
33,128
+29,513
+816% +$2.56M ﹤0.01% 3193
2020
Q3 		$278K Buy
3,615
+2,855
+376% +$219K ﹤0.01% 4223
2020
Q2 		$65K Buy
+760
New +$68.9K ﹤0.01% 4736
2019
Q2 		– Sell
-8,524
Closed -$606K – 5972
2019
Q1 		$606K Sell
8,524
-16,465
-66% -$1.04M ﹤0.01% 4106
2018
Q4 		$1.99M Buy
24,989
+4,254
+21% +$971K ﹤0.01% 3279
2018
Q3 		$9.67M Sell
20,735
-349
-2% -$140K ﹤0.01% 2233
2018
Q2 		$8.38M Buy
21,084
+670
+3% +$238K ﹤0.01% 2285
2018
Q1 		$6.24M Buy
20,414
+5,870
+40% +$1.67M ﹤0.01% 2393
2017
Q4 		$4.28M Buy
14,544
+2,373
+19% +$1.04M ﹤0.01% 2804
2017
Q3 		$7.13M Buy
12,171
+209
+2% +$111K ﹤0.01% 2272
2017
Q2 		$7.13M Buy
11,962
+3,816
+47% +$1.69M ﹤0.01% 2223
2017
Q1 		$3.5M Sell
8,146
-525
-6% -$221K ﹤0.01% 2670
2016
Q4 		$4.46M Sell
8,671
-1,592
-16% -$930K ﹤0.01% 2545
2016
Q3 		$4.39M Buy
10,263
+220
+2% +$86K ﹤0.01% 2345
2016
Q2 		$4.21M Buy
+10,043
New +$4.22M ﹤0.01% 2399

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's RNAC Position: Q1 2026 in Review

JP Morgan Chase reduced its Cartesian Therapeutics (RNAC) stake by 25% in Q1 2026, selling an estimated $10.5K and leaving 4,413 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6455.

JP Morgan Chase first reported a position in RNAC in Q2 2016 and has held it in 36 quarters since. The position peaked at $9.67M in Q3 2018. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • JP Morgan Chase held 4,413 shares of Cartesian Therapeutics worth $25.9K as of Q1 2026.
  • JP Morgan Chase sold 1,476 Cartesian Therapeutics shares in Q1 2026, an estimated $10.5K.
  • Cartesian Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6455 holding.
  • JP Morgan Chase first reported a position in Cartesian Therapeutics in Q2 2016 and has held it in 36 quarters since.
  • JP Morgan Chase's Cartesian Therapeutics position peaked at $9.67M in Q3 2018.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.